Physician profile
Steven Jared Potter
NPI 1407922446
$962.52
in general payments reported to CMS, 2019-2025
23 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.67 · 2021: $132 · 2022: $109 · 2023: $77.78 · 2024: $276 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.77 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $134.95 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $96.13 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $85.19 | 2022-2025 | Rexulti |
| Boston Scientific Corporation | $83.97 | 2021-2025 | General - Pain Management |
| Glaxosmithkline, LLC. | $64.88 | 2020-2021 | |
| Antares Pharma, INC. | $62.92 | 2025 | Xyosted |
| Lilly USA, LLC | $43.62 | 2023-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $40.82 | 2024-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $38.67 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $37.32 | 2024 | Breztri, Airsupra |
| Shield Therapeutics INC | $33.60 | 2024 | |
| Amgen INC. | $32.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.58 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.61 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $20.07 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.67 | 2021 | |
| Lundbeck LLC | $19.04 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.66 | 2022 | |
| Mylan Specialty L.P. | $16.94 | 2024 | Yupelri |
| Idorsia Pharmaceuticals US INC | $16.38 | 2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $15.55 | 2021 | |
| Pfizer INC. | $15.52 | 2024 | |
| Novo Nordisk INC | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.